Saluda Medical’s Australian arm has secured ASIC approval to bypass standalone audited financial reports, cutting costs and streamlining compliance.
- ASIC exempts Saluda Australia from standalone audits
- Relief applies from FY 26 onwards
- Consolidated US GAAP reports suffice
- Deed of cross guarantee benefits creditors
- Saluda to maintain ASX reporting compliance
ASIC Relief Eases Financial Reporting Burden
Saluda Medical (ASX:SLD) has won a regulatory reprieve from the Australian Securities and Investments Commission (ASIC) that exempts its wholly owned Australian subsidiary, Saluda Medical Pty Ltd, from preparing and auditing standalone financial reports for the 2026 financial year and beyond. This relief aligns with ASIC’s Corporations (Wholly-Owned Companies) Instrument 2016/785 and effectively removes duplicative reporting obligations under Australian law.
The exemption means Saluda Australia will no longer need to produce separate audited financial statements or directors’ reports, nor provide these documents directly to members. Instead, Saluda Medical’s consolidated financial statements, prepared under US GAAP, will incorporate the subsidiary’s results. This approach is expected to reduce administrative costs and complexity for the group.
Deed of Cross Guarantee Adds Creditor Protection
The relief is contingent on Saluda Australia entering into a deed of cross guarantee (DOCG) with the parent company, which extends creditor protections by making the subsidiary party to the DOCG. This legal structure is designed to provide assurance to creditors despite the absence of standalone financial reports.
Saluda Medical also commits to releasing its Appendix 4E preliminary final report for FY 26 by 31 August 2026, ensuring ongoing compliance with ASX Listing Rule 4.3A. This maintains transparency for investors despite the subsidiary’s reporting exemption.
Cost Savings and Reporting Consistency Drive the Move
The primary rationale behind seeking ASIC’s relief is to avoid the cost and duplication of auditing Saluda Australia’s financials separately from the consolidated group accounts. The company already prepares consolidated US GAAP financial statements, which include the subsidiary’s results, making separate Australian audits redundant.
Moreover, lodging a single consolidated report reduces the risk of conflicting financial information reaching shareholders and creditors. This streamlining is particularly relevant given Saluda’s recent operational momentum, including a Q2 FY26 global revenue surge and expanded market reach following regulatory approvals.
Regulatory Relief Supports Growth Strategy
Saluda’s relief from Australian financial reporting obligations comes at a time when the company is scaling its commercial operations globally. The company’s innovative closed-loop neuromodulation platform, including the Evoke® System, is gaining traction in treating chronic neurological pain. This follows regulatory milestones such as the recent CE approval for EVA™ technology that broaden Saluda’s market footprint in Europe and Australia.
By simplifying financial compliance, Saluda can focus resources on commercial execution and innovation rather than administrative overheads. However, the relief depends on Saluda maintaining its consolidated US GAAP reporting and the deed of cross guarantee, meaning any future changes in these arrangements could affect the exemption’s validity.
Bottom Line?
Saluda’s ASIC relief trims reporting costs and complexity, but investors should watch for any shifts in accounting standards or corporate guarantees that might alter this arrangement.
Questions in the middle?
- Will Saluda maintain the deed of cross guarantee indefinitely?
- How might changes in US GAAP or ASIC rules impact this relief?
- Could further cost savings be realised through similar regulatory approvals?